Latest Arrowhead Research Corp (ARWR) Headlines
Regulatory Approvals, Pricing of Public Offering, Stock Price Movements, and Financial Reports - Analyst Notes on Arrowhead, ANI, OraSure, Rigel, and Foundation Medicine
PR Newswire - Mon Mar 10, 11:30AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), OraSure Technologies, Inc. (NASDAQ: OSUR), Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Arrowhead to Present at Barclays Global Healthcare Conference
Business Wire - Mon Mar 10, 6:30AM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that President and CEO, Christopher Anzalone, Ph.D., will present at the Barclays Global Healthcare Conference on Thursday, March 13, 2014 at 8:00 a.m. EDT at the Loews Hotel in Miami, Florida.
Arrowhead Research Surges as It Advances Its Drug for Hepatitis B into Phase 2
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 07, 1:30PM CST
Shares in speculative biotechnology company Arrowhead , which was one of 2013's best performing biotechs , jumped nearly 25% following news its lead compound is heading into phase 2 trials. The company won approval from Hong Kong regulators to...
Pre-Market Top Gainers Analysis: Smith & Wesson Holding, DryShips, Arrowhead Research and ZBB Energy
PR Newswire - Thu Mar 06, 11:38AM CST
The US markets saw a mixed sentiment on Wednesday, March 05, 2014, with the NASDAQ Composite closing at 4,357.97, up 0.14%, the Dow Jones Industrial Average ending the session at 16,360.18, down 0.22% and the S&P 500 edging 0.01% lower to finish the trading session at 1,873.81. During the session gains in the Financials, Consumer Discretionary and Materials sectors positively impacted the broader market, while some retraction also came in from Energy, Utilities and Telecommunication Services sectors. A number of stocks saw large movements, including Smith & Wesson Holding Corporation (NASDAQ: SWHC), DryShips Inc. (NASDAQ: DRYS), Arrowhead Research Corporation (NASDAQ: ARWR), and ZBB Energy Corporation (NYSE MKT: ZBB), which were amongst the top gainers for the session. Free research on these five companies can be accessed at:
Critical Alerts For Autodesk, Pfizer, Arrowhead Research, Discover Financial, and Vodafone Released By InvestorsObserver
PR Newswire - Thu Mar 06, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ADSK, PFE, ARWR, DFS, and VOD.
Nasdaq stocks posting largest percentage increases
AP - Wed Mar 05, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
3 Stocks Making Massive 1-Day Moves
David Williamson, The Motley Fool - Motley Fool - Wed Mar 05, 4:52PM CST
In the biotech space today, three stocks made absolutely massive moves, with each popping or dropping by more than 20% in a single day. First up is Peregrine , the day's biggest winner by far, up nearly 50% today on the announcement that it would...
Why Peregrine Pharmaceuticals, Arrowhead Research, and Maxwell Technologies Are Today's 3 Best Stock
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 05, 4:15PM CST
Following yesterday's surge to a new record high close by the S&P 500 , investors have to be quite pleased with the tight trading range and minor dip in the iconic index today despite mixed economic data. On the bright side, the latest...
Why Arrowhead Research Corp. Shares Surged
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 05, 1:55PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Arrowhead Research , a clinical-stage...
Why Arrowhead Research (ARWR) His a Five-Year High Today
at The Street - Wed Mar 05, 1:31PM CST
Arrowhead Research (ARWR) hit a five-year high of $27.21 on Wednesday after the FDA approved a phase 2a trial of its hepatitis B drug ARC-520, and several analysts consequently praised the company. Deutsche Bank initiated coverage on the stock with a...
Today's Top Performers In Health Care
at The Street - Wed Mar 05, 11:02AM CST
TheStreet highlights 3 stocks pushing the health care sector higher today.
Arrowhead Surges As Analysts Laud Hepatitis B Drug
at Investor's Business Daily - Wed Mar 05, 10:14AM CST
Biotech Arrowhead Research (ARWR), whose stock price had already doubled this year, jumped another 20% on the stock market today on a pair of bullish analyst initiation reports. After the close Tuesday, Michael Yee of RBC Capital Markets launched...
Arrowhead Research Corporation (ARWR) Marked As A Dead Cat Bounce Stock
at The Street - Mon Mar 03, 8:45AM CST
Trade-Ideas LLC identified Arrowhead Research Corporation (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate
Arrowhead Receives Regulatory Approval to Begin Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520
Business Wire - Mon Mar 03, 6:30AM CST
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520, its RNAi-based drug candidate for the treatment of chronic hepatitis B virus (HBV) infection. The Hong Kong Department of Health issued a Certificate for Clinical Trial, allowing the Company to proceed with its planned single-dose study of ARC-520 in two cohorts at two dose levels to be conducted at Queen Mary Hospital and Prince of Wales Hospital in Hong Kong. A site initiation was completed and patient screening will initiate shortly. The Company expects top line study results to be available in the third quarter of 2014.
Which Themes in Biotech Today are Bankable?
Chris Ahlstrand, The Motley Fool - Motley Fool - Tue Feb 25, 5:30PM CST
Sometimes the best way to get started in biotech investing is to analyze specific technologies within the industry. The science and our knowledge of how diseases work is constantly evolving, and every now and then breakthroughs take place which...
Arrowhead Closes Underwritten Offering with Gross Proceeds of $120 Million
Business Wire - Mon Feb 24, 7:59AM CST
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that on February 24, 2014 it closed the previously announced underwritten offering of 6,325,000 shares of common stock, which included shares issued upon the exercise in full by the underwriters of their option to purchase 825,000 additional shares. The offering was priced at $18.95 per share and the company received gross proceeds of approximately $120 million, before deducting underwriting discounts, commissions, and other offering expenses payable by the company. Jefferies LLC, Barclays Capital Inc., and Deutsche Bank Securities acted as joint book-runners for the offering. Piper Jaffray & Co. acted as lead manager for the offering and Trout Capital acted as a financial advisor to the Company.
Arrowhead Listing Upgraded to NASDAQ Global Select Market
Business Wire - Fri Feb 21, 6:30AM CST
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received notice that the NASDAQ Listing Qualifications Department has approved an application to upgrade the listing of the Company's securities from the NASDAQ Capital Market to the NASDAQ Global Select Market, effective with the opening of business on February 21, 2014. The NASDAQ Global Select Market is the segment for public companies that meet the highest listing standards of NASDAQ, with requirements that include market value, financial, and liquidity measurements. The Company's stock will continue to trade under the ticker symbol "ARWR" after the upgrade.
Arrowhead to Present at RBC Capital Markets' Global Healthcare Conference
Business Wire - Thu Feb 20, 3:01PM CST
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that President and CEO, Christopher Anzalone, Ph.D., will present at the 2014 RBC Capital Markets' Global Healthcare Conference on Wednesday, February 26, 2014 at 3:30 p.m. EST at the New York Palace Hotel.
Regulatory Approvals, Pricing of Public Offering, Stock Price Movements, and Financial Reports - Analyst Notes on Arrowhead, ANI, OraSure, Rigel, and Foundation Medicine
PR Newswire - Mon Mar 10, 11:30AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), OraSure Technologies, Inc. (NASDAQ: OSUR), Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Arrowhead to Present at Barclays Global Healthcare Conference
Business Wire - Mon Mar 10, 6:30AM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that President and CEO, Christopher Anzalone, Ph.D., will present at the Barclays Global Healthcare Conference on Thursday, March 13, 2014 at 8:00 a.m. EDT at the Loews Hotel in Miami, Florida.
Arrowhead Research Surges as It Advances Its Drug for Hepatitis B into Phase 2
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 07, 1:30PM CST
Shares in speculative biotechnology company Arrowhead , which was one of 2013's best performing biotechs , jumped nearly 25% following news its lead compound is heading into phase 2 trials. The company won approval from Hong Kong regulators to...
Pre-Market Top Gainers Analysis: Smith & Wesson Holding, DryShips, Arrowhead Research and ZBB Energy
PR Newswire - Thu Mar 06, 11:38AM CST
The US markets saw a mixed sentiment on Wednesday, March 05, 2014, with the NASDAQ Composite closing at 4,357.97, up 0.14%, the Dow Jones Industrial Average ending the session at 16,360.18, down 0.22% and the S&P 500 edging 0.01% lower to finish the trading session at 1,873.81. During the session gains in the Financials, Consumer Discretionary and Materials sectors positively impacted the broader market, while some retraction also came in from Energy, Utilities and Telecommunication Services sectors. A number of stocks saw large movements, including Smith & Wesson Holding Corporation (NASDAQ: SWHC), DryShips Inc. (NASDAQ: DRYS), Arrowhead Research Corporation (NASDAQ: ARWR), and ZBB Energy Corporation (NYSE MKT: ZBB), which were amongst the top gainers for the session. Free research on these five companies can be accessed at:
Critical Alerts For Autodesk, Pfizer, Arrowhead Research, Discover Financial, and Vodafone Released By InvestorsObserver
PR Newswire - Thu Mar 06, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ADSK, PFE, ARWR, DFS, and VOD.
Nasdaq stocks posting largest percentage increases
AP - Wed Mar 05, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
3 Stocks Making Massive 1-Day Moves
David Williamson, The Motley Fool - Motley Fool - Wed Mar 05, 4:52PM CST
In the biotech space today, three stocks made absolutely massive moves, with each popping or dropping by more than 20% in a single day. First up is Peregrine , the day's biggest winner by far, up nearly 50% today on the announcement that it would...
Why Peregrine Pharmaceuticals, Arrowhead Research, and Maxwell Technologies Are Today's 3 Best Stock
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 05, 4:15PM CST
Following yesterday's surge to a new record high close by the S&P 500 , investors have to be quite pleased with the tight trading range and minor dip in the iconic index today despite mixed economic data. On the bright side, the latest...
Why Arrowhead Research Corp. Shares Surged
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 05, 1:55PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Arrowhead Research , a clinical-stage...
Why Arrowhead Research (ARWR) His a Five-Year High Today
at The Street - Wed Mar 05, 1:31PM CST
Arrowhead Research (ARWR) hit a five-year high of $27.21 on Wednesday after the FDA approved a phase 2a trial of its hepatitis B drug ARC-520, and several analysts consequently praised the company. Deutsche Bank initiated coverage on the stock with a...
Today's Top Performers In Health Care
at The Street - Wed Mar 05, 11:02AM CST
TheStreet highlights 3 stocks pushing the health care sector higher today.
Arrowhead Surges As Analysts Laud Hepatitis B Drug
at Investor's Business Daily - Wed Mar 05, 10:14AM CST
Biotech Arrowhead Research (ARWR), whose stock price had already doubled this year, jumped another 20% on the stock market today on a pair of bullish analyst initiation reports. After the close Tuesday, Michael Yee of RBC Capital Markets launched...
Arrowhead Research Corporation (ARWR) Marked As A Dead Cat Bounce Stock
at The Street - Mon Mar 03, 8:45AM CST
Trade-Ideas LLC identified Arrowhead Research Corporation (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate
Arrowhead Receives Regulatory Approval to Begin Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520
Business Wire - Mon Mar 03, 6:30AM CST
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520, its RNAi-based drug candidate for the treatment of chronic hepatitis B virus (HBV) infection. The Hong Kong Department of Health issued a Certificate for Clinical Trial, allowing the Company to proceed with its planned single-dose study of ARC-520 in two cohorts at two dose levels to be conducted at Queen Mary Hospital and Prince of Wales Hospital in Hong Kong. A site initiation was completed and patient screening will initiate shortly. The Company expects top line study results to be available in the third quarter of 2014.
Which Themes in Biotech Today are Bankable?
Chris Ahlstrand, The Motley Fool - Motley Fool - Tue Feb 25, 5:30PM CST
Sometimes the best way to get started in biotech investing is to analyze specific technologies within the industry. The science and our knowledge of how diseases work is constantly evolving, and every now and then breakthroughs take place which...
Arrowhead Closes Underwritten Offering with Gross Proceeds of $120 Million
Business Wire - Mon Feb 24, 7:59AM CST
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that on February 24, 2014 it closed the previously announced underwritten offering of 6,325,000 shares of common stock, which included shares issued upon the exercise in full by the underwriters of their option to purchase 825,000 additional shares. The offering was priced at $18.95 per share and the company received gross proceeds of approximately $120 million, before deducting underwriting discounts, commissions, and other offering expenses payable by the company. Jefferies LLC, Barclays Capital Inc., and Deutsche Bank Securities acted as joint book-runners for the offering. Piper Jaffray & Co. acted as lead manager for the offering and Trout Capital acted as a financial advisor to the Company.
Arrowhead Listing Upgraded to NASDAQ Global Select Market
Business Wire - Fri Feb 21, 6:30AM CST
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received notice that the NASDAQ Listing Qualifications Department has approved an application to upgrade the listing of the Company's securities from the NASDAQ Capital Market to the NASDAQ Global Select Market, effective with the opening of business on February 21, 2014. The NASDAQ Global Select Market is the segment for public companies that meet the highest listing standards of NASDAQ, with requirements that include market value, financial, and liquidity measurements. The Company's stock will continue to trade under the ticker symbol "ARWR" after the upgrade.
Arrowhead to Present at RBC Capital Markets' Global Healthcare Conference
Business Wire - Thu Feb 20, 3:01PM CST
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that President and CEO, Christopher Anzalone, Ph.D., will present at the 2014 RBC Capital Markets' Global Healthcare Conference on Wednesday, February 26, 2014 at 3:30 p.m. EST at the New York Palace Hotel.
